TGFB1 and prostate cancer: While Sharp1 was shown to suppress EMT and metastasis by attenuating NOTCH1 signaling in endometrial cancer cells [111] and TGF-β-associated EMT in prostate cancer PC-3 cells [110], Sharp2 favored TGF-β-associated EMT [103] and interplayed with NOTCH1 to favor cell growth and invasiveness [110].